{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:38:37Z","timestamp":1785209917112,"version":"3.55.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,2,1]]},"DOI":"10.2169\/internalmedicine.4163-24","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T22:11:04Z","timestamp":1724796664000},"page":"455-458","source":"Crossref","is-referenced-by-count":1,"title":["A CML Patient Carrying &lt;i&gt;BCR::ABL1&lt;\/i&gt; Splicing Variants Did Not Experience Blast Crisis for 15 Years without Responding to Various TKIs"],"prefix":"10.2169","volume":"64","author":[{"given":"Fumi","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Dokkyo Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Dokkyo Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Nannya","sequence":"additional","affiliation":[{"name":"Department of Pathology and Tumor Biology, Kyoto University, Japan"},{"name":"Division of Hematopoietic Disease Control, Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisako","family":"Iso","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Dokkyo Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Dokkyo Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Dokkyo Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Pathology and Tumor Biology, Kyoto University, Japan"},{"name":"Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinuko","family":"Mitani","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Dokkyo Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol 34: 2333-2340, 2016.","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30: 1044-1054, 2016.","DOI":"10.1038\/leu.2016.5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Poudel G, Tolland MG, Hughes TP, Pagani IS. Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia. Cancers 14: 3300, 2022.","DOI":"10.3390\/cancers14143300"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Soverini S, Branford S, Nicolini FE, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res 38: 10-20, 2014.","DOI":"10.1016\/j.leukres.2013.09.011"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369: 1783-1796, 2013.","DOI":"10.1056\/NEJMoa1306494"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 132: 393-404, 2018.","DOI":"10.1182\/blood-2016-09-739086"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 381: 2315-2326, 2019.","DOI":"10.1056\/NEJMoa1902328"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sherbenou DW, Hantschel O, Turaga L, et al. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia 22: 1184-1190, 2008.","DOI":"10.1038\/leu.2008.65"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. O&apos;Hare T, Zabriskie MS, Eide CA, et al. The BCR-ABL<sup>35INS<\/sup> insertion\/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood 118: 5250-5254, 2011.","DOI":"10.1182\/blood-2011-05-349191"},{"key":"10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"10. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in &quot;good-risk&quot; chronic granulocytic leukemia. Blood 63: 789-799, 1984.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90: 850-858, 1998.","DOI":"10.1093\/jnci\/90.11.850"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118: 686-692, 2011.","DOI":"10.1182\/blood-2010-12-319038"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ochi Y, Kon A, Sakata T, et al. Combined cohesin-RUNX1 deficiency synergistically perturbs chromatin looping and causes myelodysplastic syndromes. Cancer Discov 10: 836-853, 2020.","DOI":"10.1158\/2159-8290.CD-19-0982"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Laudadio J, Deininger MW, Mauro MJ, Druker BJ, Press RD. An intron-derived insertion\/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn 10: 177-180, 2008.","DOI":"10.2353\/jmoldx.2008.070128"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yuda J, Miyamoto T, Odawara J, et al. Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response. Cancer Sci 108: 2204-2212, 2017.","DOI":"10.1111\/cas.13353"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Walter MJ, Ding L, Shen D, et al. Recurrent <i>DNMT3A<\/i> mutations in patients with myelodysplastic syndromes. Leukemia 25: 1153-1158, 2011.","DOI":"10.1038\/leu.2011.44"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hou HA, Kuo YY, Liu CY, et al. <i>DNMT3A<\/i> mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 119: 559-568, 2012.","DOI":"10.1182\/blood-2011-07-369934"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Branford S, Kim DDH, Apperley JF, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia 33: 1835-1850, 2019.","DOI":"10.1038\/s41375-019-0512-y"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Perusini MA, \u017d\u00e1\u010dkov\u00e1 D, Kim T, et al. Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes. Blood Adv 8: 2361-2372, 2024.","DOI":"10.1182\/bloodadvances.2023012127"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Marc\u00e9 S, Cort\u00e9s M, Zamora L, et al. A thirty-five nucleotides <i>BCR-ABL1<\/i> insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML). Exp Mol Pathol 99: 16-18, 2015.","DOI":"10.1016\/j.yexmp.2015.04.007"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Berman E, Jhanwar S, Hedvat C, et al. Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1<sup>35INS<\/sup>. Leuk Res 49: 108-112, 2016.","DOI":"10.1016\/j.leukres.2016.08.006"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/3\/64_4163-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T03:37:21Z","timestamp":1738381041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/3\/64_4163-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4163-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"article-number":"4163-24"}}